

Holger Jahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8908018/publications.pdf>

Version: 2024-02-01

114
papers

6,621
citations

57758

44
h-index

64796

79
g-index

118
all docs

118
docs citations

118
times ranked

8973
citing authors

#	ARTICLE	IF	CITATIONS
1	Disruption of ClC-3, a Chloride Channel Expressed on Synaptic Vesicles, Leads to a Loss of the Hippocampus. <i>Neuron</i> , 2001, 29, 185-196.	8.1	480
2	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2424-2437.	3.8	434
3	Memory loss in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2013, 15, 445-454.	3.7	393
4	Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism. <i>Archives of General Psychiatry</i> , 2003, 60, 92.	12.3	386
5	Amyloid β peptide ratio 42/40 but not β 42 correlates with phospho τ in patients with low and high CSF β 40 load. <i>Journal of Neurochemistry</i> , 2007, 101, 1053-1059.	3.9	237
6	MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0126423.	2.5	184
7	Metyrapone as Additive Treatment in Major Depression. <i>Archives of General Psychiatry</i> , 2004, 61, 1235.	12.3	163
8	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. <i>Molecular Psychiatry</i> , 2010, 15, 138-145.	7.9	156
9	Investigations on CXCL13 in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2015, 72, 180.	9.0	142
10	Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. <i>Neurology</i> , 2012, 78, 379-386.	1.1	141
11	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015, 36, 601-607.	3.1	125
12	Site-specific phosphorylation of the purified receptor for calcium-channel blockers by cAMP- and cGMP-dependent protein kinases, protein kinase C, calmodulin-dependent protein kinase II and casein kinase II. <i>FEBS Journal</i> , 1988, 178, 535-542.	0.2	120
13	Leptin: a modulator of alcohol craving?. <i>Biological Psychiatry</i> , 2001, 49, 782-787.	1.3	116
14	Elevation of β -Amyloid Peptide 2 β 42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 42645-42657.	3.4	115
15	Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept study. <i>Journal of Psychiatric Research</i> , 2010, 44, 339-346.	3.1	115
16	High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 822-832.	3.7	114
17	Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers. <i>PLoS ONE</i> , 2011, 6, e26540.	2.5	105
18	Pharmacological Relapse Prevention of Alcoholism: Clinical Predictors of Outcome. <i>European Addiction Research</i> , 2005, 11, 83-91.	2.4	96

#	ARTICLE	IF	CITATIONS
19	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 4-10.	1.9	96
20	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. <i>Neurobiology of Aging</i> , 2008, 29, 812-818.	3.1	94
21	Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. <i>Experimental Neurology</i> , 2010, 223, 366-370.	4.1	92
22	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 404-417.	1.5	90
23	Poly ϵ -GP in cerebrospinal fluid links <i>C9orf72</i> -associated dipeptide repeat expression to the asymptomatic phase of <i>ALS</i> / <i>FTD</i> . <i>EMBO Molecular Medicine</i> , 2017, 9, 859-868.	6.9	90
24	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 239-247.	1.9	89
25	Anxiolyticlike Effects of Atrial Natriuretic Peptide on Cholecystokinin Tetrapeptide-Induced Panic Attacks. <i>Archives of General Psychiatry</i> , 2001, 58, 371.	12.3	86
26	Serum neurofilament light chain in behavioral variant frontotemporal dementia. <i>Neurology</i> , 2018, 91, e1390-e1401.	1.1	85
27	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. <i>Journal of Psychiatric Research</i> , 2019, 113, 137-140.	3.1	81
28	Executive functioning in obsessive-compulsive disorder, unipolar depression, and schizophrenia. <i>Archives of Clinical Neuropsychology</i> , 2002, 17, 477-483.	0.5	73
29	The patient with dementia, the caregiver and the doctor: cognition, depression and quality of life from three perspectives. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 604-610.	2.7	73
30	Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism. <i>Journal of Psychiatric Research</i> , 2005, 39, 545-551.	3.1	72
31	A multicenter ¹ H-MRS study of the medial temporal lobe in AD and MCI. <i>Neurology</i> , 2009, 72, 1735-1740.	1.1	72
32	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. <i>PLoS ONE</i> , 2018, 13, e0197329.	2.5	68
33	Impact of comorbid depressive symptoms on nonverbal memory and visuospatial performance in obsessive-compulsive disorder. <i>Cognitive Neuropsychiatry</i> , 2003, 8, 261-272.	1.3	66
34	Hypothalamic-Pituitary-Adrenocortical Axis Activity: A Target of Pharmacological Anticraving Treatment?. <i>Biological Psychiatry</i> , 2006, 60, 74-76.	1.3	60
35	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 84.	6.2	58
36	Leptin as a Possible Modulator of Craving for Alcohol. <i>Archives of General Psychiatry</i> , 2001, 58, 509.	12.3	55

#	ARTICLE	IF	CITATIONS
37	Central and Peripheral Administration of Atriopeptin Is Anxiolytic in Rats. <i>Neuroendocrinology</i> , 1997, 65, 210-215.	2.5	54
38	Asymmetrical Dimethylarginine Is Increased in Plasma and Decreased in Cerebrospinal Fluid of Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 58-64.	1.5	51
39	Is withdrawal-induced anxiety in alcoholism based on $\hat{\mu}$ -endorphin deficiency?. <i>Psychopharmacology</i> , 2002, 162, 433-437.	3.1	50
40	Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide. <i>Neuropeptides</i> , 2003, 37, 362-368.	2.2	49
41	Alcohol self-administration, craving and HPA-axis activity: an intriguing relationship. <i>Psychopharmacology</i> , 2002, 164, 239-240.	3.1	48
42	The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. <i>Life Sciences</i> , 2003, 73, 1835-1845.	4.3	48
43	A combination of galantamine and memantine modifies cognitive function in subjects with amnesic MCI. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 544-548.	3.3	48
44	Genetic interaction of <i>PICALM</i> and <i>APOE</i> is associated with brain atrophy and cognitive impairment in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S269-76.	0.8	47
45	Mineralocorticoid Receptor-Mediated Inhibition of the Hypothalamic-Pituitary-Adrenal Axis in Aged Humans. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2003, 58, B900-B905.	3.6	46
46	Dimensional structure of the Hamilton Depression Rating Scale in patients with obsessive-compulsive disorder. <i>Psychiatry Research</i> , 2004, 125, 171-180.	3.3	44
47	A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. <i>Journal of Psychopharmacology</i> , 2018, 32, 668-677.	4.0	44
48	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2020, 19, 1310-1318.	3.7	43
49	Association between fully automated MRI-based volumetry of different brain regions and neuropsychological test performance in patients with amnesic mild cognitive impairment and Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 335-344.	3.2	42
50	Involvement of NMDA receptors in alcohol-mediated behavior: mice with reduced affinity of the NMDA R1 glycine binding site display an attenuated sensitivity to ethanol. <i>Biological Psychiatry</i> , 2003, 53, 345-351.	1.3	41
51	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. <i>PLoS ONE</i> , 2014, 9, e100812.	2.5	41
52	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. <i>Neurology</i> , 2015, 84, 1261-1268.	1.1	41
53	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients - An Atlas-Based Volumetric MRI Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 45.	3.4	40
54	Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. <i>Journal of Psychiatric Research</i> , 1998, 32, 37-48.	3.1	36

#	ARTICLE	IF	CITATIONS
55	Use of proteomic methods in the analysis of human body fluids in Alzheimer research. <i>Electrophoresis</i> , 2012, 33, 3617-3630.	2.4	35
56	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	3.1	34
57	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 11.	3.4	34
58	Suicide attempts with mirtazapine overdose without complications. <i>Biological Psychiatry</i> , 1998, 44, 925-926.	1.3	33
59	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 503-511.	1.9	33
60	Dimethylarginines, Homocysteine Metabolism, and Cerebrospinal Fluid Markers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 751-758.	2.6	32
61	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 349-356.	1.9	31
62	Adjunctive use of reboxetine in schizophrenia. <i>European Psychiatry</i> , 2004, 19, 366-369.	0.2	27
63	Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1090-1100.	6.4	26
64	C-type natriuretic peptide exerts effects opposing those of atrial natriuretic peptide on anxiety-related behaviour in rats. <i>Brain Research</i> , 1998, 792, 358-360.	2.2	25
65	No Effects of Antidepressants on Negative Symptoms in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 686-690.	1.4	23
66	The Latent Dementia Phenotype $\hat{\Gamma}$ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 547-560.	2.6	23
67	Clinico-genetic findings in 509 frontotemporal dementia patients. <i>Molecular Psychiatry</i> , 2021, 26, 5824-5832.	7.9	23
68	Quantifying progression in primary progressive aphasia with structural neuroimaging. <i>Alzheimer's and Dementia</i> , 2021, 17, 1595-1609.	0.8	22
69	Sleep Endocrine Effects of the $\hat{\Gamma}^2$ -Hydroxysteroiddehydrogenase Inhibitor Metyrapone. <i>Sleep</i> , 2003, 26, 823-829.	1.1	21
70	Effects of treatment with acamprosate on $\hat{\Gamma}^2$ -endorphin plasma concentration in humans with high alcohol preference. <i>Neuroscience Letters</i> , 2006, 404, 103-106.	2.1	21
71	Amyloid- $\hat{\Gamma}^2$ Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 903-916.	1.7	18
72	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. <i>Cortex</i> , 2019, 117, 33-40.	2.4	17

#	ARTICLE	IF	CITATIONS
73	C-type natriuretic peptide exerts stimulatory effects on the corticotropin-releasing hormone-induced secretion of hormones in normal man. <i>European Journal of Endocrinology</i> , 1997, 136, 388-393.	3.7	16
74	Centrifugal Phe-Met-Arg-Phe-NH ₂ -like immunoreactive innervation of the retina in a non-teleost bony fish, <i>Lepisosteus osseus</i> . <i>Neuroscience Letters</i> , 1999, 264, 33-36.	2.1	16
75	CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks. <i>Journal of Psychiatric Research</i> , 2010, 44, 1148-1153.	3.1	16
76	Augmented Stress-Induced Alcohol Drinking and Withdrawal in Mice Lacking Functional Natriuretic Peptide-A Receptors. <i>Alcohol and Alcoholism</i> , 2010, 45, 13-16.	1.6	15
77	The applause sign in frontotemporal lobar degeneration and related conditions. <i>Journal of Neurology</i> , 2019, 266, 330-338.	3.6	15
78	Î±-Helical-corticotropin-releasing hormone reverses angiogenic effects of C-type natriuretic peptide in rats. <i>Brain Research</i> , 2001, 893, 21-28.	2.2	14
79	Prolactin but not ACTH increases during sodium lactate-induced panic attacks. <i>Psychiatry Research</i> , 2002, 109, 201-205.	3.3	14
80	Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings. <i>European Neuropsychopharmacology</i> , 2004, 14, 337-339.	0.7	14
81	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment" data from the Dementia Competence Network. <i>Journal of Neural Transmission</i> , 2022, 129, 477-486.	2.8	14
82	APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 389-401.	2.6	13
83	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 27.	6.2	13
84	Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 482-486.	2.3	10
85	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. <i>Cortex</i> , 2021, 140, 66-79.	2.4	10
86	Natriuretic peptides and panic disorder: therapeutic prospects. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 381-386.	2.8	9
87	Copeptin " A potential endocrine surrogate marker of CCK-4-induced panic symptoms?. <i>Psychoneuroendocrinology</i> , 2017, 76, 14-18.	2.7	9
88	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 62.	6.2	9
89	Intraperitoneal Atrial Natriuretic Peptide Attenuates Anxiety-related Behaviour during Alcohol Withdrawal in Mice. <i>Pharmacopsychiatry</i> , 2014, 47, 97-100.	3.3	8
90	Alzheimer's disease: Elevated pigment epithelium-derived factor in the cerebrospinal fluid is mostly of systemic origin. <i>Journal of the Neurological Sciences</i> , 2017, 375, 123-128.	0.6	8

#	ARTICLE	IF	CITATIONS
91	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 41.	6.2	8
92	Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. <i>Depression and Anxiety</i> , 2006, 23, 139-144.	4.1	7
93	Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced nephropathy: Preliminary results. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 673-678.	4.8	7
94	B-spline-based stereotactical normalization of brain FDG PET scans in suspected neurodegenerative disease: Impact on voxel-based statistical single-subject analysis. <i>NeuroImage</i> , 2010, 50, 994-1003.	4.2	7
95	A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease. <i>Neuroscience Letters</i> , 2014, 566, 115-119.	2.1	7
96	Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 526-534.	2.6	5
97	Mirtazapine-Induced Galactorrhea: A Case Report. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, E13-E14.	1.8	5
98	Genetic Risk Factors for Depression in Alzheimer's Disease Patients. <i>Current Alzheimer Research</i> , 2013, 10, 72-81.	1.4	5
99	Harman and norharman plasma levels in weaned alcoholics: correlations with depression and tobacco smoking. <i>Addiction Biology</i> , 2000, 5, 437-441.	2.6	4
100	Pharmacological treatment of non-Alzheimer dementias. <i>Current Opinion in Psychiatry</i> , 2006, 19, 642-648.	6.3	4
101	Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men. <i>Psychoneuroendocrinology</i> , 2010, 35, 1438-1445.	2.7	4
102	Predicting disease progression in behavioral variant frontotemporal dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12262.	2.4	4
103	Steroid-synthesis inhibition in depression: a good idea?. <i>Lancet Psychiatry</i> , 2016, 3, 92-93.	7.4	3
104	Overnight suppression of HPA axis after mineralocorticoid receptor stimulation: A sleep endocrine study. <i>Psychiatry Research</i> , 2015, 227, 65-70.	3.3	2
105	Therapeutic Drug Monitoring of Naltrexone and $^6\beta$ -Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges. <i>Alcohol and Alcoholism</i> , 2019, 54, 51-55.	1.6	2
106	MicroRNA Profiling of Alzheimer's Disease Cerebrospinal Fluid. <i>Methods in Molecular Biology</i> , 2018, 1750, 93-107.	0.9	2
107	A novel computerized algorithm to detect microstructural brainstem pathology in Parkinson's disease using standard 3 Tesla MR imaging. <i>Journal of Neurology</i> , 2014, 261, 1968-1975.	3.6	1
108	Recent advances in structural MRI in Parkinson's disease and atypical parkinsonian syndromes. <i>Neurodegenerative Disease Management</i> , 2012, 2, 517-533.	2.2	0

#	ARTICLE	IF	CITATIONS
109	Nonfluent Variant of Primary Progressive Aphasia With Right Hemisphere Atrophy â€“ A Phenotype of Corticobasal Degeneration?. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 420-421.	1.5	0
110	Atrial Natriuretic Peptide, the Hypothalamicâ€“Pituitaryâ€“Adrenal Axis, and Panic Attacks. , 2019, , 177-186.		0
111	Uso auxiliar de la reboxetina en la esquizofrenia. <i>European Psychiatry (Ed EspaÃ±ola)</i> , 2005, 12, 107-110.	0.0	0
112	Proteomics as a New Tool for Biomarker-Discovery in Neuropsychiatric Disorders. , 2009, , 103-111.		0
113	Factors influencing atrophy progression in primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
114	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. , 2014, 9, e100812.		0